Information de reference pour ce titreAccession Number: | 00129039-200203000-00007.
|
Author: | Rosenthal, Seth I. M.D.; Depowski, Peter L. M.D.; Sheehan, Christine E. B.S.; Ross, Jeffrey S. M.D.
|
Institution: | From the Department of Pathology and Laboratory Medicine Albany Medical Center, Albany, New York, U.S.A. Dr. Ross is Consultant Medical Director of Ventana Medical Systems, Inc.
|
Title: | Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer.[Miscellaneous Article]
|
Source: | Applied Immunohistochemistry & Molecular Morphology. 10(1):40-46, March 2002.
|
Abstract: | Background: Abnormal expression of the HER-2/ neu oncogene, a tyrosine kinase-type transmembrane growth factor receptor localized to chromosome 17q, has been associated with poor prognosis and the prediction of therapy response in invasive breast cancer. The comparative incidence and significance of HER-2/ neu gene amplification for lobular and ductal breast cancer have not been previously characterized.
Design: Formalin-fixed, paraffin-embedded primary breast cancer tissue sections from 71 women diagnosed with invasive lobular carcinoma were tested for HER-2/ neu gene amplification by fluorescence in situ hybridization (FISH) method using the Ventana unique sequence probe (Ventana Medical Systems, Tucson, AZ). A series of 106 cases of invasive ductal carcinoma was similarly processed and tested. Lymph node status was available for 155 (88%) of the 177 cases and 82 (46%) were lymph node-negative (LN-) and 73 (41%) were lymph node-positive (LN+). Patients were treated for a mean of 65 months (range 1-169 months).
Results: 9 of 71 (13%) cases of lobular cancer featured HER-2/ neu gene amplification, whereas 51(48%) of 106 cases of ductal cancer showed amplification (P < 0.0001). On univariate analysis of combined lobular and ductal cases, HER-2/ neu gene amplification detected by FISH predicted disease-related death (P < 0.0001). HER-2/ neu gene amplification also predicted disease-related death in lobular cases alone (P = 0.003), LN+ lobular cases separately (P = 0.019), and LN- and LN+ ductal cases separately and alone (P < 0.0001). Multivariate analysis of the lobular group alone revealed that LN+ status (P = 0.015) and stage (P = 0.01) were independent predictors of disease-related death, and HER-2/ neu gene amplification reached near significance (P = 0.086). In the ductal carcinoma group alone, HER-2/ neu gene amplification (P = 0.03), lymph node status (P = 0.0001), tumor stage (P = 0.0001), and tumor grade (P = 0.044) were independent predictors of overall disease survival.
Conclusions: HER-2/ neu gene amplification detected by FISH was identified at a significantly lower rate in lobular compared with ductal breast cancer. HER-2/ neu gene amplification when present in lobular breast cancer is a significant adverse prognostic factor.
Copyright 2002 Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | Breast cancer; c-erb-B2; HER-2/ neu; FISH; Lobular; Prognosis.
|
References: | 1. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978; 42:737-69.
2. DiCostanzo D, Rosen PP, Gareen I, et al. Prognosis in infiltrating lobular carcinoma. Am J Surg Pathol 1990; 14:12-23.
3. Page DL, Kidd TE, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent cancer predicted by more extensive disease. Hum Pathol 1991; 22:1232-9.
4. Ladekarl M, Sorensen FB. Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast. Cancer 1993; 72:2602-11.
5. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia: long term risk of breast cancer and relation to other factors. Cancer 1996; 78:1024-34.
6. Ashikari R, Huvos AG, Urban JA, et al. Infiltrating lobular carcinoma of the breast. Cancer 1973; 31:110-6.
7. Davis RP, Nora PF, Kooy RG, et al. Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg 1979; 114:485-8.
8. Smith DB, Howell A, Wagstaff J. Infiltrating lobular carcinoma of the breast. Eur J Surg Oncol 1985; 11:33-6.
9. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Path 1991; 15:334-49.
10. Porter-Jordan K, Lippman ME. Overview of the biologic markers in breast cancer. Hematol Oncol Clin N Amer 1994; 8:73-100.
11. Popescu NC, King CR, Kraus MH. Localization of the erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989: 4:362-6.
12. Maguire Jr, HC Greene MI. The neu (c-erb B-2) oncogene. Semin Oncol 1989; 16:148-55.
13. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987; 235:177-82.
14. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
15. Tandon AK, Clark GM, Chamness GC, et al. HER-2/ neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7:1120-8.
16. O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relation between c-erb B-2 overexpression, S-phase fraction and prognosis in breast cancer. Br J Cancer 1991; 63:444-6.
17. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erb B-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8:103-12.
18. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30 year follow up. J Clin Oncol 1992; 10:1044-8.
19. Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of HER-2/ neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic factors, histologic natures, and prognosis. Cancer 1995; 75:1320-6.
20. Clark GM, McGuire WL. Follow up study of HER-2/ neu amplification in primary breast cancer. Cancer Res 1991; 51:944-8.
21. Ali IU, Campbell G, Lidereau R, et al. Lack of evidence for theprognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncol Res 1988; 3:139-46.
22. Press MF, Bernstein L, Thomas PA, et al. Her-2/ neu gene amplification characterized by fluorescence in situ hybridization; poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15:2894-904.
23. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34:791-808.
24. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19:2334-56.
25. Xing W-R, Gilchrist KW, Harris CP, et al. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 1996; 39:203-12.
26. Depowski PL, Brien TP, Sheehan CE, et al. Prognostic significance of p34cdc2 cyclin dependent kinase and MIB1 overexpression, and HER-2/ neu gene amplification detected by fluorescence in-situ hybridization in breast cancer. Am J Clin Pathol 1999; 112:459-69.
27. Porter PL, Garcia R, Moe R, et al. C-erbB-2 oncogene protein in in-situ and invasive lobular breast neoplasia. Cancer 1991; 68:331-4.
28. Rosen PP, Lesser LM, Arroyo CD, et al. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995; 13:821-30.
29. Iochim E, Kamina S, Athanassiadou S, et al. The prognostic significance of epidermal growth factor receptor (EGFR), c-erbB-2, Ki-67, and PCNA expression in breast cancer. Anticancer Res 1996; 16:3141-7.
30. Rudas M, Neumayer R, Gnant MF, et al. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 1997; 33:39-44.
31. Elston CW, Ellis IO. Pathologic prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long term follow up. Histopathology 1991; 19:403-10.
32. DiCostanzo D, Rosen PP, Gareen I, et al. Prognosis of infiltrating lobular carcinoma. An analysis of "classical" and variant tumors. Am J Surg Pathol 1990; 14:12-23.
33. Foote FW, Stuart FW. A histologic classification of carcinoma of the breast. Surgery 1946; 19:74-99.
34. Tavasoli FA. Infiltrating carcinoma: common and familiar special types. In:Pathology of the breast. Norwalk, CT: Appleton and Lang, 1992;401-40.
35. Ross JS, Fletcher JA. The HER-2/ neu oncogene: prognostic factor, predictive factor and target for therapy. The Oncologist 1998; 3:237-52.
36. Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-6.
37. Tetu B, Brisson J. Prognostic significance of HER-2/ neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73:235-42.
|
Language: | English.
|
Document Type: | RESEARCH.
|
Journal Subset: | Clinical Medicine. Physical Science & Engineering.
|
ISSN: | 1541-2016
|
NLM Journal Code: | dr0, 100888796
|
Annotation(s) | |
|
|